| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f02dc2b2dfa70dd2b7093fc3a4753438 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-6018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10345 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 |
| filingDate |
2009-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37e7cf51929e887530bf133750b23886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd8c52360437f3b6080b121196a03d76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30a48e0999f72a92001eade07047ae39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15231cfa240c0a632ec54389d88cff82 |
| publicationDate |
2011-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2379586-A1 |
| titleOfInvention |
Oncolytic adenoviral vectors and methods and uses related thereto |
| abstract |
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077156-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11401529-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3725888-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11130968-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3725323-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3725322-A1 |
| priorityDate |
2008-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |